Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Abstract Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.) Fla.), 2009-03, Vol.130 (3), p.252-258
Hauptverfasser:	El Fassi, Daniel, Banga, J. Paul, Gilbert, Jacqueline A, Padoa, Carolyn, Hegedüs, Laszlo, Nielsen, Claus H
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Animals Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antibody Formation - drug effects Autoantibodies - blood Autoantibody Autoimmunity B lymphocyte Bioactivity Biological and medical sciences CD20 CHO Cells Cricetinae Cricetulus Cyclic AMP - metabolism Endocrinopathies Fundamental and applied biological sciences. Psychology Fundamental immunology Graves Disease - drug therapy Graves Disease - immunology Graves' disease Humans Immunoglobulin Immunoglobulins, Thyroid-Stimulating - drug effects Immunoglobulins, Thyroid-Stimulating - metabolism Immunologic Factors - therapeutic use Immunotherapy Medical sciences Non tumoral diseases. Target tissue resistance. Benign neoplasms Rituximab Thyroid. Thyroid axis (diseases)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!